TITLE

Effect of Human Immunodeficiency Virus Type 1 (H1V-1) Subtype on Disease Progression in Persons from Rakai, Uganda, with Incident HIV-1 Infection

AUTHOR(S)
Kiwanuka, Noah; Laeyendecker, Oliver; Robb, Merlin; Kigozi, Godfrey; Arroyo, Miguel; McCutchan, Francine; Eller, Leigh Anne; Eller, Michael; Makumbi, Fred; Birx, Deborah; Wabwire-Mangen, Fred; Serwadda, David; Sewankambo, Nelson K.; Quinn, Thomas C.; Wawer, Maria; Gray, Ronald
PUB. DATE
March 2008
SOURCE
Journal of Infectious Diseases;3/1/2008, Vol. 197 Issue 5, p707
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Human immunodeficiency virus type 1 (HIV-1) subtypes differ in biological characteristics that may affect pathogenicity. Methods. We determined the HIV-1 subtype-specific rates of disease progression among 350 HIV-1 seroconverters. Subtype, viral load, and CD4+ cell count were determined. Cox proportional hazards regression modeling was used to estimate adjusted hazard ratios (HRs) of progression to acquired immunodeficiency syndrome (AIDS) (defined as a CD4+ cell count of ⩽250 cells/mm³) and to AIDS-associated death. Results. A total of 59.1% of study subjects had subtype D strains, 15.1% had subtype A, 21.1% had intersubtype recombinant subtypes, 4.3% had multiple subtypes, and 0.3% had subtype C. Of the 350 subjects, 129 (37%) progressed to AIDS, and 68 (19.5%) died of AIDS. The median time to AIDS onset was shorter for persons with subtype D (6.5 years), recombinant subtypes (5.6 years), or multiple subtypes (5.8 years), compared with persons with subtype A (8.0 years; P = .022). Relative to subtype A, adjusted HRs of progression to AIDS were 2.13 [95% confidence interval {CI}, 1.10-4.11] for subtype D, 2.16 [95% CI, 1.05-4.45] for recombinant subtypes, and 4.40 [95% CI, 1.71-11.31 for multiple subtypes. The risk of progression to death was significantly higher for subtype D (adjusted HR, 5.65; 95% CI, 1.37-23.4), recombinant subtypes (adjusted HR, 6.70; 95% CI, 1.56-28.8), and multiple subtypes (adjusted HR, 7.67; 95% CI, 1.27-46.3), compared with subtype A. Conclusions. HIV disease progression is affected by HIV-1 subtype. This finding may impact decisions on when to initiate antiretroviral therapy and may have implications for future trials of HIV-1 vaccines aimed at slowing disease progression.
ACCESSION #
31661053

 

Related Articles

  • Simian fetal brain progenitor cells for studying viral neuropathogenesis. Iwata, Naoko; Yoshida, Hiroaki; Tobiume, Minoru; Ono, Fumiko; Shimazaki, Takuya; Sata, Tetsutaro; Nakajima, Noriko // Journal of NeuroVirology;Feb2007, Vol. 13 Issue 1, p11 

    The pathogenesis of neurologic dysfunctions caused by human immunodeficiency virus type 1 (HIV-1) infection is not yet well understood. Simian immunodeficiency virus (SIV) infection of macaques is an important animal model for HIV-1 infection. This is the first report to characterize brain...

  • SHIV Infection Protects Against Heterologous Pathogenic SHIV Challenge in Macaques: A Gold-Standard for HIV-1 Vaccine Development? Sealy, Robert; Xiaoyan Zhan; Lockey, Timothy D.; Martin, Louis; Blanchard, James; Traina-Dorge, Vicki; Hurwitz, Julia L. // Current HIV Research;Sep2009, Vol. 7 Issue 5, p497 

    A current debate in the HIV-1 vaccine field concerns the ability of an immunodeficiency virus to elicit a protective response. One argument is that HIV-1 superinfections are frequent in healthy individuals, because virus evades conventional immune surveillance, a serious obstacle to vaccine...

  • CCR5 Inhibitors: Promising yet Challenging. Clotet, Bonaventura // Journal of Infectious Diseases;7/15/2007, Vol. 196 Issue 2, p178 

    The author reflects on the significance of CCR5 inhibitors, an antiretroviral (ARV) drugs that prevent human immunodeficiency viruses (HIV) entry. The antiretroviral agents are used for macrophage-tropic viruses to block the fusion between the viral and the cellular membranes. The author further...

  • HIV-1: The Confounding Variables of Virus Neutralization. Nara, Peter L.; Lin, George // Current Drug Targets - Infectious Disorders;Jun2005, Vol. 5 Issue 2, p157 

    The development of an effective vaccine against HIV-1 would be greatly facilitated by the ability to elicit potent, high affinity antibodies that are capable of broad neutralization, viral inactivation and protection against infection and/or disease. New insights into the structure and function...

  • Application of the Polyvalent Approach to HIV-1 Vaccine Development. Hurwitz, Julia L.; Slobod, Karen S.; Lockey, Tim D.; Wang, Shixia; Chou, Te-Hui W.; Lu, Shan // Current Drug Targets - Infectious Disorders;Jun2005, Vol. 5 Issue 2, p143 

    One major obstacle to the design of a global HIV-1 vaccine is viral diversity. Presently, data suggest that a single antigen will not suffice to generate broadly reactive neutralizing antibodies to protect all individuals against all subtypes of HIV-1 infection. While some of the neutralizing...

  • Inactivated- or Killed-Virus HIV/AIDS Vaccines. Sheppard, Haynes W. // Current Drug Targets - Infectious Disorders;Jun2005, Vol. 5 Issue 2, p131 

    Inactivated or “killed” virus (KV) is a “classical approach that has produced safe and effective human and veterinary vaccines but has received relatively little attention in the effort to develop an HIV/AIDS vaccine. Initially, KV and rgp120 subunit vaccines were the two most...

  • Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion. Veazey, Ronald S.; Klasse, Per Johan; Schader, Susan M.; Qinxue Hu; Ketas, Thomas J.; Min Lu; Marx, Preston A.; Dufour, Jason; Colonno, Richard J.; Shattock, Robin J.; Springer, Martin S.; Moore, John P. // Nature;11/3/2005, Vol. 438 Issue 7064, p99 

    Human immunodeficiency virus type 1 (HIV-1) continues to spread, principally by heterosexual sex, but no vaccine is available. Hence, alternative prevention methods are needed to supplement educational and behavioural-modification programmes. One such approach is a vaginal microbicide: the...

  • Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIVmac239. Bin Jia; Ng, Sharon K.; DeGottardi, M. Quinn; Piatak Jr., Michael; Yuste, Eloísa; Carville, Angela; Mansfield, Keith G.; Wenjun Li; Richardson, Barbra A.; Lifson, Jeffrey D.; Evans, David T. // PLoS Pathogens;Jan2009, Vol. 5 Issue 1, p1 

    Strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to elicit protective immunity against wild-type SIVmac239 infection of rhesus macaques by two different vaccine regimens. Six animals were inoculated at 8-week intervals...

  • Changes in surveillance of HIV and AIDS.  // BMJ: British Medical Journal (International Edition);7/22/89, Vol. 298 Issue 6693, p222 

    Reports the changes in the surveillance of HIV and AIDS in Great Britain. Inclusion of deaths of people infected with HIV; Synopsis of diagnostic methods for AIDS indicator diseases; Classification of manifestation of HIV infections.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics